Evidence map›Paper›PMID 37870695›Full record

ReviewCurrent treatment options in oncology2023

Developing Strategies to Improve the Efficacy of CAR-T Therapy for Acute Myeloid Leukemia.

Shujing Guo, Xuejin Gao, Mahara Sadhana, Ruiting Guo, Jile Liu, Wenyi Lu, Ming Feng Zhao

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current treatment options in oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.9field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Shujing GuoFirst Center, Clinic College of Tianjin Medical University, Tianjin, 300192, China.
Xuejin GaoEmergency Department, Tianjin First Central Hospital, Tianjin, 300192, China.
Mahara SadhanaFirst Center, Clinic College of Tianjin Medical University, Tianjin, 300192, China.
Ruiting Guo *First Center, Clinic College of Tianjin Medical University, Tianjin, 300192, China.
Jile Liu *First Center, Clinic College of Tianjin Medical University, Tianjin, 300192, China.
Wenyi LuDepartment of Hematology, Tianjin First Central Hospital, Tianjin, 300192, China. Luwenyi0323@163.com.
Ming Feng ZhaoDepartment of Hematology, Tianjin First Central Hospital, Tianjin, 300192, China. mingfengzhao@sina.com.
Tianjin Medical University · CN

Funding

General Project of National Natural Science Foundation of China 81970180Key Medical Discipline(Speciaty) Construction Project TJWJ2023XK010Key projects of Tianjin Applied Basic Research and Multi-Investment Fund 21JCZDJC01240Science and Technology Project of Tianjin Municipal Health Committee TJWJ2022QN030Science and Technology Project of Tianjin Municipal Health Committee TJWJ2022XK018Tianjin Key Medical Discipline(Specialty) Construction Project TJYXZDXK-056BTianjin Municipal Bureau of Public Health ZC20074Tianjin Municipal Natural Science Foundation 22JCQQNJC00820Tianjin Municipal Transportation Commission Science and Technology Development Plan Project TJWJ2023QN027
6 · The paper itself

Abstract

opinion statementAcute myeloid leukemia (AML) is a fatal blood malignancy. With the development of immunotherapy, particularly chimeric antigen receptor T cells (CAR-T), the treatment of AML has undergone a significant change. Despite its advantages, CAR-T still faces a number of limitations and challenges while treating AML. Finding novel targets, altering the structure of CAR to increase efficacy while lowering side effects, and using double-target CAR and logic circuits are typical examples of key to answer these problems. With the advancement of gene editing technology, gene editing of tumor cells or normal cells to create therapeutic effects has grown in popularity. Additionally, the combination of multiple drugs is routinely used to address some of the obstacles and difficulties associated with CAR-T therapy. The review's primary goal was to summarize recent strategies and developments of CAR-T therapy for AML.

Indexed as

Leukemia, Myeloid, AcuteReceptors, Chimeric AntigenHumansImmunotherapyImmunotherapy, AdoptiveT-LymphocytesReceptors, Chimeric AntigenAcute myeloid leukemiaCAR-TCombination strategiesGene modificationLogic circuit

Identifiers

PMID37870695
OpenAlexW4387866212

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.